“Personalized medicine (PM) has been described as ‘the right drug, for
the right patient, at the right time, at the right dose.’ National
health systems and private payers would like to add ‘at the right price,
as well.”
This according to Angelo DePalma, a
writer/consultant whose opinions appear in an article posted last week
in Eye for Pharma.
An individualized treatment based on each patient’s unique
physical/biological needs, PM is contrary to the model most
pharmaceutical developers have been using for years. But it is taking
hold and could be a boon to an industry which has been watching “big
pharma’s one-size-fits-all approach to drug development,” unravel for
some time.
Its future looks bright, according to DePalma, because it reallocates
healthcare resources more equitably and in the direction of patient
benefit. “At best,” says DePalma, “the industry would recoup lost
revenues through better patient compliance and higher prices, at least
in some markets.” Still, some experts say wide availability of
personalized medicine is 10-20 years off.
YOU influence personalized medicine
As we’ve been reporting here and in our sister publication Healthcare Packaging, innovation in prescription and OTCs is key to bracing the pharma industry’s profits.
Dec 14, 2010
Recommended
Machinery Basics
Annual Outlook Report: Automation & Robotics
What's in store for CPGs in 2025 and beyond? <i>Packaging World</i> editors explore the survey responses from 118 brand owners, CPG, and FMCG <i>Packaging World</i> readers for its new Annual Outlook Report.
Download
2024 PACK EXPO Innovations Reports
Exclusive access: Packaging World editor-curated reports revealing PACK EXPO's most groundbreaking technologies across food, healthcare, and machinery sectors. Each report features truly innovative solutions selected from hundreds of exhibitors by our expert team. Transform your operations with just one click.
Access Now
